Dosing of U-100 insulin and associated outcomes among Medicare enrollees with type 1 or type 2 diabetes
Elizabeth L Eby,1 Kate Van Brunt,2 Cynthia Brusko,3 Bradley Curtis,4 Maureen J Lage5 1Global Patient Outcomes and Real World Evidence, Eli Lilly and Co., Indianapolis IN USA; 2Eli Lilly and Co., Windlesham, UK; 3Lilly USA, LLC, Indianapolis, IN, USA; 4Eli Lilly a...
Guardado en:
Autores principales: | Eby EL, Van Brunt K, Brusko C, Curtis B, Lage MJ |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3b00f7e19d5c4ce8b901e842577cae8b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Evaluating the cost-effectiveness of insulin detemir versus neutral protamine Hagedorn insulin in patients with type 1 or type 2 diabetes in the UK using a short-term modeling approach
por: Pollock RF, et al.
Publicado: (2018) -
The value of patient-reported outcomes in patients with type 2 diabetes mellitus receiving insulin therapy: assessment of quality of life and hypoglycemia problems
por: Tat'yana Ivanovna Ionova, et al.
Publicado: (2015) -
Association Between Knowledge of Hypoglycemia and Likelihood of Experiencing Hypoglycemia Among Patients with Insulin-Treated Diabetes Mellitus
por: Almigbal TH
Publicado: (2021) -
RELUCTANCE OF PATIENTS WITH DIABETES MELLITUS TO INSULIN THERAPY; PSYCHOLOGICAL INSULIN RESISTANCE
por: Umair Ali, et al.
Publicado: (2021) -
Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
por: Ivan Ivanovich Dedov, et al.
Publicado: (2014)